Skip to main content
SpringerLink
Log in

4th Austrian pancreas day: a summary of the surgical management of exocrine pancreatic neoplasms

  • Short Communication
  • Published:
European Surgery Aims and scope Submit manuscript

Summary

Background

In the twenty-first century management of pancreatic diseases remains a challenge for surgeons, gastroenterologists, anesthesiologists, pathologists, radiologists, and oncologists. While the techniques of pancreatic resections have not changed within the last decades, nowadays multimodal neoadjuvant treatment strategies offer curative surgical therapy to a higher percentage of patients. Furthermore, new knowledge has emerged about the biology and treatment of cystic lesions of the pancreas.

Methods

We summarized the surgical topics of the upcoming meeting entitled “4th Austrian Pancreas Day”.

Results

Even after decades of intense research the ductal adenocarcinoma of the pancreas stays a deadly disease. A curative R0 resection remains the only treatment potentially prolonging overall survival. Esposito et al. as well as Verbeke et al. demonstrated that axial slicing and extensive tissue sampling, raises the R1 resection rate up to 85 %, compared to R1 rates of 10–20 % in older series with basic pathological workup. In locally and advanced and borderline resectable pancreatic cancer, novel chemotherapeutic regimes like Folfirinox in combination with or without radiotherapy proved to offer satisfying response rates, making curative resection feasible in more patients. At the same time, the number of patients incidentally diagnosed with cystic lesion of the pancreas is continuously rising. However, only some of these patients need pancreatic surgery while others can be safely observed. In 2012 the International Association of Pancreatology has revised their guidelines for the management of mucinous cystic neoplasms and intraductal papillary mucinous neoplasms, deemphasizing cyst size as a worrisome feature.

Conclusions

Today, patients with pancreatic neoplasms need to be managed by an experienced interdisciplinary team. In such professional setting it should by our goal to curatively resect as much as possible patients with pancreatic malignancies and at the same time reduce the number of unnecessary operations of benign cystic neoplasms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Alexakis N, Halloran C, Raraty M, et al. Current standards of surgery for pancreatic cancer. Br J Surg. 2004;91(11):1410–27.

    Article  PubMed  CAS  Google Scholar 

  2. Buchler MW, Wagner M, Schmied BM, et al. Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy. Arch Surg. 2003;138(12):1310–4 (discussion 1315).

    Google Scholar 

  3. Carpelan-Holmstrom M, Nordling S, Pukkala E, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut. 2005;54(3):385–7.

    Article  PubMed  CAS  Google Scholar 

  4. Diener MK, Knaebel HP, Heukaufer C, et al. A systematic review and meta-analysis of pylorus-preserving versus classical pancreaticoduodenectomy for surgical treatment of periampullary and pancreatic carcinoma. Ann Surg. 2007;245(2):187–200.

    Article  PubMed  Google Scholar 

  5. Friess H, Kleeff J, Kulli C, et al. The impact of different types of surgery in pancreatic cancer. Eur J Surg Oncol. 1999;25(2):124–31.

    Article  PubMed  CAS  Google Scholar 

  6. Gudjonsson B. Cancer of the pancreas. 50 years of surgery. Cancer. 1987;60(9):2284–303.

    Article  PubMed  CAS  Google Scholar 

  7. Hartel M, Wente MN, Hinz U, et al. Effect of antecolic reconstruction on delayed gastric emptying after the pylorus-preserving Whipple procedure. Arch Surg. 2005;140(11):1094–9.

    Article  PubMed  Google Scholar 

  8. Kleeff J, Reiser C, Hinz U, et al. Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg. 2007;245(4):566–72.

    Article  PubMed  Google Scholar 

  9. Park YC, Kim SW, Jang JY, et al. Factors influencing delayed gastric emptying after pylorus-preserving pancreatoduodenectomy. J Am Coll Surg. 2003;196(6):859–65.

    Article  PubMed  Google Scholar 

  10. Pedrazzoli S, DiCarlo V, Dionigi R, et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study—Lymphadenectomy Study Group. Ann Surg. 1998;228(4):508–17.

    Article  PubMed  CAS  Google Scholar 

  11. Pedrazzoli S, Pasquali C, Sperti C. Role of surgery in the treatment of bilio-pancreatic cancer: the European experience. Semin Oncol.2002;29(6 Suppl 20):23–30.

    Google Scholar 

  12. Schafer M, Mullhaupt B, Clavien PA. Evidence-based pancreatic head resection for pancreatic cancer and chronic pancreatitis. Ann Surg. 2002;236(2):137–48.

    Article  PubMed  Google Scholar 

  13. Stojadinovic A, Brooks A, Hoos A, et al. An evidence-based approach to the surgical management of resectable pancreatic adenocarcinoma. J Am Coll Surg. 2003;196(6):954–64.

    Article  PubMed  Google Scholar 

  14. Tani M, Terasawa H, Kawai M, et al. Improvement of delayed gastric emptying in pylorus-preserving pancreaticoduodenectomy: results of a prospective, randomized, controlled trial. Ann Surg. 2006;243(3):316–20.

    Article  PubMed  Google Scholar 

  15. Wagner M, Redaelli C, Lietz M, et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004;91(5):586–94.

    Article  PubMed  CAS  Google Scholar 

  16. White RR, Shah AS, Tyler DS. Pancreatic cancer since Halsted: how far have we come and where are we going? Ann Surg. 2003;238(6 Suppl):132–44 (Discussion S145–7).

    Google Scholar 

  17. Yeo CJ, Cameron JL, Sohn TA, et al. Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome. Ann Surg. 1999;229(5):613–22 (Discussion 622–4).

    Google Scholar 

  18. Z’Graggen K, Uhl W, Friess H, Buchler MW. How to do a safe pancreatic anastomosis. J Hepatobiliary Pancreat Surg. 2002;9(6):733–7.

    Article  PubMed  Google Scholar 

  19. Sultana A, Tudur Smith C, Cunningham D, et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer. 2007;96:1183–90.

    Article  PubMed  CAS  Google Scholar 

  20. Sa Cunha A, Rault A, Laurent C, et al. Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas. J Am Coll Surg. 2005;201:359–65.

    Article  PubMed  Google Scholar 

  21. Castillo CF, Adsay NV. Intraductal papillary mucinous neoplasms of the pancreas. YGAST. 2011;139(3):708–13.e2.

    Google Scholar 

  22. Fernandez-Del Castillo C. Surgical treatment of intraductal papillary mucinous neoplasms of the pancreas: the conservative approach. J Gastrointest Sur. 2002;6(5):660–1.

    Article  Google Scholar 

  23. Matthaei H, Norris AL, Tsiatis AC, et al. Clinicopathological characteristics and molecular analyses of multifocal Intraductal Papillary Mucinous Neoplasms of the Pancreas. Ann Sur. 2012;255(2):326–33.

    Article  Google Scholar 

  24. Mino-Kenudson M, Fernandez-Del Castillo C, Baba Y, et al. Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut. 2011;60(12):1712–20.

    Article  PubMed  Google Scholar 

  25. Partelli S, Fernandez-Del Castillo C, Bassi C, et al. Invasive Intraductal Papillary Mucinous Carcinomas of the Pancreas. Ann Surg. 2010;251(3):477–82.

    Article  PubMed  Google Scholar 

  26. Tanaka M, Fernandez-Del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12(3):183–97.

    Article  PubMed  Google Scholar 

  27. Falconi M, Salvia R, Bassi C, et al. Clinicopathological features and treatment of intraductal papillary mucinous tumour of the pancreas. Br J Surg. 2001;88(3):376–81.

    Article  PubMed  CAS  Google Scholar 

  28. Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. Ann Surg. 2001;234(3):313–21 (Discussion 321–2).

    Google Scholar 

Download references

Conflict of interest

The authors declare that there are no actual or potential conflicts of interest in relation to this article.

Author information

Authors and Affiliations

  1. Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18–20, 1190, Vienna, Austria

    K. Sahora, M. Schindl & M. Gnant

Authors
  1. K. Sahora
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Schindl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Gnant
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Sahora.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sahora, K., Schindl, M. & Gnant, M. 4th Austrian pancreas day: a summary of the surgical management of exocrine pancreatic neoplasms. Eur Surg 45, 277–281 (2013). https://doi.org/10.1007/s10353-013-0229-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10353-013-0229-5

Keywords

Search

Navigation